Skip to main content
. 2018 Jan 23;24:438–447. doi: 10.12659/MSM.905393

Figure 4.

Figure 4

Kaplan-Meier curves for recurrence-free survival rates according to pT classification, pN classification, tumor grade, tumor size, CIS, LVI, STSM and CASC2 expression in 122 UCB patients. (A) Recurrence-free survival of pT classification, stratified by pT0-1, pT2, pT3 vs. pT4; (B) recurrence-free survival of pN classification, stratified by pN0 vs. pN+; (C) recurrence-free survival of tumor grade, stratified by high grade vs. low grade; (D) recurrence-free survival of tumor size, stratified by ≥3 cm vs. <3 cm; (E) recurrence-free survival of CIS, stratified by present vs. absent; (F) recurrence-free survival of LVI, stratified by present vs. absent; (G) recurrence-free survival of STSM, stratified by positive vs. negative; and (H) recurrence-free survival of CASC2 expression, stratified by low expression vs. high expression; CASC2 – cancer susceptibility candidate 2; LVI – lymphovascular invasion; CIS – concomitant carcinoma in situ; STSM – soft tissue surgical margin.